Application of micheliolide dimethylamine

A technology of dimethylamine and lactone, which is applied in the field of application of michelactone dimethylamine, can solve the problems of easy drug resistance, and achieve the effect of improving liver function, good therapeutic effect and easy acceptance

Active Publication Date: 2016-04-27
TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE +1
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nucleosides and other drugs used to treat liver fibrosis are only likely to achieve durable responses with long-term treatment and are prone to drug resistance
There are still varying degrees of controversy about the efficacy of some drugs used to treat liver fibrosis clinically.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of micheliolide dimethylamine
  • Application of micheliolide dimethylamine
  • Application of micheliolide dimethylamine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Establishment of mouse liver fibrosis model and pharmacodynamic detection of ACT001

[0042] Experimental method and steps:

[0043] 1. Establishment of mouse liver fibrosis model and drug treatment

[0044] 1.1 Establishment of mouse liver fibrosis model

[0045] The 36 mice were randomly divided into three groups: normal group, control group (model group without administration), and ACT001 group, with 12 mice in each group. The normal group each subcutaneous injection of 0.15ml of normal saline on the back; the control group (model non-administration group) and ACT001 group each subcutaneous injection of 0.15ml containing 40% CCl 4 CCl 4 - Suspension in edible oil; injected twice a week.

[0046] 1.2 Administration and treatment of mice with liver fibrosis

[0047] In the third week after modeling, the mice were given drug treatment. The normal group and the control group were intragastrically administered with 0.9% normal saline of 0.1ml each time, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of micheliolide dimethylamine (ACT001) to preparation of medicines for treating hepatic fibrosis. The micheliolide dimethylamine (ACT001) is capable of reversing and inhibiting hepatic fibrosis level of organisms, inhibiting hyperplasia of fibrocytes in livers, improving liver blood supply, promoting hepatocyte regeneration and reducing liver inflammatory effects, thereby being remarkably effective in treatment of hepatic fibrosis.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to the application of mimilactone dimethylamine. Background technique [0002] Microlactone dimethylamine is a derivative of balanolide, which is prepared from the natural extract parthenolide, and is referred to as ACT001 in this article. Parthenolide is a sesquiterpene lactone compound purified from the herb tansy, which has anti-inflammatory, anti-tumor, anti-platelet aggregation and other characteristics. It has anti-inflammatory effect by inhibiting the expression of tumor necrosis factor (TNF-α), interleukin-1 (IL-1), IL-12 and cyclooxygenase-2 (COX-2); by inhibiting The activation and phosphorylation of NF-кB promote the apoptosis of cancer cells, and at the same time inhibit the production of L-8 and vascular endothelial growth factor (VEGF), which plays an anti-tumor role; the current research on ACT001 is mainly used for Treatment of diseases such as skin infections, m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P1/16
Inventor 饶子和孙涛陈悦周红刚刘艳荣刘慧娟孙波张成玉张强荆学双刘学强樊云静
Owner TIANJIN INT JOINT ACADEMY OF BIOTECH & MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap